Publication | Open Access

Mass spectrometry–based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells

Tumor BiologyMedicineReceptor Tyrosine KinaseBiological Mass SpectrometryCancer Cell BiologyKinase MelkProtein KinaseCancer CellsMitotic EntryRadiation OncologyCancer BiologyCell BiologyCancer Research